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ARB Compared with non-ARB in Preventing Cardiac 
Events in High Risk Hypertensive Patients: 
An Evidence Based Case Report
Alvin Nursalim,* Yoga Yuniadi#
Background: Hig� ris� �yper�ensive pa�ien�s �ave an increased ris� o� 
developing cardiovascular co�plica�ion. I� is be��er �o use a proven car-
diopro�ec�ive drugs �o reduce blood pressure in �ig� ris� �yper�ensive 
pa�ien�s. Angio�ensin II �ecep�or Bloc�er (A�B) is one �ype o� an�i�yper-
�ensive drugs wi�� cardiopro�ec�ive e��ec� �or �yper�ensive pa�ien�s wi��ou� 
o��er ris� �ac�or. W�e��er cardiopro�ec�ive e��ec� o� A�B also apply �or a 
�ore speci�ic popula�ion suc� as �ig� ris� �yper�ensive pa�ien�s need �o 
be inves�iga�ed.
Aim: To de�er�ine ��e e��icacy o� A�B co�pared �o non-A�Bs in preven�ing 
cardiac even� in a �ore speci�ic popula�ion, suc� as �ig� ris� �yper�ensive 
pa�ien�s.
Methods: A searc� was conduc�ed on �ubMed and Coc�rane. T�e selec-
�ion o� �i�le and abs�rac� was done using inclusion and exclusion cri�erias. 
T�ree original ar�icles were �ound and used as ��e evidence �or ��e clinical 
ques�ion. T�e selec�ed s�udies were cri�ically appraised �or validi�y, i�por-
�ance and applicabili�y.
Result: According �o �awada e� al, ��e blood pressure lowering e��ec� 
was si�ilar be�ween valsar�an and non-A�B groups. T�e cardiovascular 
even�s in valsar�an group is lower co�pared �o non-A�B groups (rela�ive 
ris�: 0.54, 95% con�idence in�erval 0.4-0.7, p< 0.001). T�e ad�inis�ra-
�ion o� valsar�an as co�pared �o non-A�B, also reduce ��e occurence o� 
angina pec�oris (�ela�ive ris� : 0.52, 95% Con�idence In�erval 0.31–0.86, � 
=0.01058). Co�n JN e� al s�owed ��a� ��ere was no signi�ican� di��erences 
in ��e candesar�an group in �er�s o� �o�al dea�� and pri�ary endpoin�s. 
T�e only signi�ican� �inding in ��is ar�icle was ��e lower ra�e  o� diabe�es 
�elli�us in ��e candesar�an group. 
Conclusion: Valsar�an, as co�pared �o non-A�B, reduce cardic even� in 
�ig� ris� �yper�ensive pa�ien�s.
(J Kardiol Indones. 2012;33:91-8)
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Latar belakang: Pasien hipertensi dengan risiko tinggi mempunyai kemungkinan lebih tinggi mendapatkan komplikasi 
kardiovaskular. Pada pasien hipertensi risiko tinggi lebih baik digunakan obat hipertensi yang memiliki efek kardioprotektif. 
Angiotensin II Receptor Blocker (ARB) adalah salah satu golongan obat hipertensi yang memiliki efek kardioprotektif pada 
pasien hipertensi tanpa risiko. Apakah ARB juga efektif untuk menurunkan kejadian kardiovaskular baru atau perburukan 
kardiovaskular pada populasi hipertensi dengan risiko tinggi?
Tujuan: Mengetahui efektivitas ARB dibandingkan non-ARB dalam menurunkan komplikasi kardiovaskular pada pasien 
hipertensi dengan risiko tinggi.
Metode: Pencarian terstruktur dilakukan menggunakan Pubmed dan Cochrane.  Setelah dilakukan penapisan judul dan ab-
strak, Tiga studi ditemukan yang kemudian digunakan penulis.Studi ini ditelaah dengan menggunakan kriteria yang mencakup 
validity, importance, danapplicability untuk menentukan derajat kegunaan studi.
Hasil: Berdasarkan studi oleh Sawada et al, valsartan memiliki efek penurunan tekanan darah sebanding dengan pengobatan 
non-ARB. Komplikasi kardiovaskular lebih rendah pada kelompok valsartan dibandingkan kelompok non-ARB (relative risk: 
0.54, 95% confidence interval 0.4-0.7, p< 0.001). Valsartan menurunkan kejadian angina pectoris dibandingkan grup non-
ARB (relative risk : 0.52, 95% Confidence Interval 0.31–0.86, P =0.01058). Cohn JN et al menyimpulkan tidak ada perbe-
daan signifikan dalam pencegahan mortalitas dan parameter akhir lainnya. Namun penggunaan candesartan secara signifikan 
mengurangi kejadian diabetes.
Kesimpulan: Valsartan, dibandingkan pengobatan non-ARB, menurunkan kejadiaan kardiovaskular pada pasien hipertensi 
dengan risiko tinggi. 
(J Kardiol Indones. 2012;33:91-8)
Kata kunci: Angiotensin II receptor blocker, valsartan, hipertensi risiko tinggi, komplikasi kardiovaskular 
ARB dibandingkan non-ARB dalam 
Menurunkan Komplikasi Kardiovaskular pada 
Pasien Hipertensi dengan Risiko Tinggi:
Laporan Berbasis Bukti
Alvin Nursalim,* Yoga Yuniadi#
Clinical scenario
A 58 years old man with dyslipidemiaand type 2 
diabetes mellitus diagnosed one year ago, came to 
the outpatient clinic for a regular check up in a 
private hospital. His physical examination was within 
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normal limit except for his high blood pressure 
(150/90). He was taking an ACE-inhibitors drug for 
his hypertension, but he complained of coughing not 
long after taking the drug. Due to the high incidence 
of cardiovascular complication among diabetic 
hypertensive patients, the doctor was thinking of 
changing his hypertensive drugs regimen to maximize 
the cardioprotective effect of the drug. The doctor 
wonders whether the administration of ARB, instead 
of non-ARBs, is more effective in preventing new 
onset or worsening of cardiac complication in high 
risk hypertensive patients.
Introduction
It is well established that hypertensionis a cardiovascular 
disease risk factor. Hypertension also increases the risk 
of atherosclerosis progression.1Currently, the main 
cardiovascular disorderresponsible for the  rise in mortality 
has changed. As the substitute ofrheumatic heart disease, 
atherosclerotic is now the leading cause for cardiovascular 
mortality. It is oftenassumed that atherosclerosis is a 
disease of high-income, industrializedcountries. However, 
80% of cardiovascular mortality occur inlow-to-middle 
income countries.2Therefore, Indonesia as a developing 
country pose a high risk of having a high cardiovascular 
mortality.
High risk hypertensive patients will have an 
accelerated rate of atherosclerotic progression.In this 
report we try to determine the cardioprotective property 
of ARBs in high risk hypertensive patients (defined by 
patients withtype 2 diabetes mellitus, lipid metabolism 
abnormality, obesity, and heart failure). Dyslipidemia 
is a strong risk predictor for coronary artery disease 
(CAD)3. Diabetic patients have twice to four times 
the risk of developing CAD as compared to those 
who do not have diabetes. Concomitanthypertension 
triples the already high risk of CAD, doubles total 
mortalityand stroke risk.4
Angiotensin II Receptor Blockers (ARB) have 
protective clinical effects similar to those of Angiotensin 
Converting Enzym Inhibitors (ACE-Is)but better 
tolerated due to less side effect.5Many studies have 
investigated the comparison of ARB and non-
ARBs for stroke prevention, cardiac protection and 
renal protection.6,7 However, the efficacy of ARB 
as compared to non-ARBs to prevent new onset or 
worsening of cardiac complication on a more specific 
population, such as high risk patients need to be 
further elaborated.
The wide arrays of antihypertensive drugs 
available and therisk factors differences of each 
hypertensive patients made it tricky to choose the 
best anti-hypertensive regimen to reduce cardiac 
complication for these patients. This report is made 
to assist physician and investigate the efficacy of ARB 
compared to non-ARBs medication to prevent new 
onset or worsening of cardiac complication in high 
risk hypertensive patients.
Clinical question
Is ARB more effective compared to non-ARBs in 




The search was conducted on PubMed,® and 
Cochrane,®on Febuary 8th 2011, using the keywords 
“angiotensin receptor blocker”, “hypertension” and 




ARB[All Fields] AND (“cardiovascular system”[MeSH 
Terms] OR (“cardiovascular”[All Fields] AND “system”[All 
Fields]) OR “cardiovascular system”[All Fields] OR 
“cardiovascular”[All Fields]) AND complication[All Fields] AND 
(“epidemiology”[Subheading] OR “epidemiology”[All Fields] OR 




“Hypertension”and“ARB”and “cardiovascular complication” 26
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“cardiovascular complication”along with its synonyms 
and related terms (Table 1). ). Searchstrategy, results, 
the inclusion and exclusion criteria are shown in a 
flowchart (Figure 1).
Selection
The first selection was based on title and ab-
stract using inclusion criteriasand exclusion 
Figure 1. Flow Chart of Search Strategy
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criteria. After selection three full-text articles 
were available.
Critical Appraisal
After the selection, critical appraisal was done using 
several aspects based on Center of Evidence-based 
Medicine, University of Oxford  for therapy study 
(Table 2).
Result
Sawada T et al8 performed a study to determined 
the efficacy of valsartan  as compared to non ARBin 
preventing morbidity and mortality in high risk 
hypertensive patients.The study was a multicentre, 
prospective, randomized, open-label, blinded-
endpoint trial. A total of 3.031 high risk hypertensive 
patients were randomized to either valsartan add-on 
or non-ARB treatment (ACE-Inhibitor was excluded) 
.Patients with one or more of these risk factors is 
included: type 2 diabetes mellitus, current smoking, 
lipid metabolism abnormality, obesity (defined as BMI 
>25 kg/m2), and left ventricular hypertrophy defined 
by electrocardiogram.The endpoints to be analyzed 
include new onset or worsening cardiovascular 
events, cerebrovascular events, mortality, worsening 
of cardiac function, new occurence or exacerbation 
Table 2. Critical Appraisal of theusefull articles based on criterias by Centre of Evidence Medicine University of 
Oxford11
























































































e Result Levels of
 evidence *
Sawada et al8 + 3,301 + + + + + + + + A 1B
Kasanuki et al9 + 2049 + + + + ? + + + B 1B
Cohn J N et al10 + 5010 + + + + ? - + + C 1B
Legend: + stated clearly in the article
- not being done
? not stated clearly
*Levels of evidence based on The Oxford Centre of Evidence-based Medicine
Domain: High risk hypertensive patients
Determinant: Valsartan add-on therapy, Comparison: non-ARB therapy
Outcome: New onset and/or worsening of cardiovascular event.
A:The cardiovascular events in valsartan group was lower compared to non-ARB groups (relative 
risk: 0.54, 95% confidence interval 0.4-0.7, p< 0.001).
B:There was no significant differences in the number of total death and primary endpoints. 
The only significant finding in this study is the occurence of diabetes mellitus (Hazard ratio: 
0.37; 95% CI,0.16–0.89; P= 0.03).
C:The rate of mortality was similar in the two treatment groups. The combined endpoint of 
mortality and morbidity was significantly reduced among patients in the valsartan group as 
compared to those in the placebo group (relative risk: 0.87, 95% confidence interval 0.77-0.97, 
p= 0.009).
Jurnal Kardiologi Indonesia  
96 Jurnal Kardiologi Indonesia •  Vol. 33, No. 2 • April - Juni 2012
of arrhythmias and new occurence or exacerbation of 
diabetes mellitus. 
The blood pressure lowering effect was similar 
between valsartan andnon-ARB groups. The 
cardiovascular events was 83 out of 1517and 155 out 
of 1514 in valsartan and non-ARB groups respectively 
(Hazard ratio:0.55, 95% confidence interval 0.4-0.7, 
P=0.00001).The Control Event Rate (CER) was 
10.2%,Experimental Event Rate (EER) was 5.5%, 
Relative Risk Reduction (RRR) was 46%, Absolute 
Risk Reduction (ARR) was 4.7%  and Number Needed 
to Treat (NNT) was 21.
Another significant outcome in this study was 
the occurence of angina pectoris.The administration 
of valsartan was superior to non ARB in reducing 
angina pectoris.22 patients given valsartan had angina 
pectoris compared with 44 in non ARB group. The 
CER was 2.9%,EER was 1.5%, RRR was 48%, ARR 
was 1.4%  andNNT was 71 (Hazard ratio : 0.51, 95% 
Confidence Interval 0.3–0.9, P =0.01058).
Cerebrovascular event represented by the occurence 
of stroke also showed a significant reduction in the 
valsartan group compared to non-ARB group(Hazard 
ratio: 0.55, 95% Confidence Interval 0.3–0.9, P 
=0.01488).
Kasanuki H et al9 conducted a study to evaluate 
the afficacy of candesartan administration in reducing 
the incidence of cardiovascular events compared with 
non-ARB therapy in coronary artery disease patients 
with hypertension. A total of 2,049 patients were 
randomized to either candesartan therapy or non-ARB 
therapy (ACE-inhibitor was included). 
The result of this study showed that there was no 
significant differences in the number of total death 
and primary endpoints, which include: cardiovascular 
deaths, non fatal myocard infarction and heart failure. 
The only significant finding in this study is the 
occurence of diabetes mellitus (hazard ratio: 0.37; 95% 
CI,0.16–0.89; P= 0.03).
Cohn J L et al10 evaluated the long term effects 
of the addition of valsartan to standard therapy for 
heart failure. This study was a randomized, placebo-
controlled, double blind clinical trial. This is a large 
study involving5,010 patients from 302 centers in 16 
countries.Patients with heart failure were randomly 
assigned to received 160 mg of valsartan or placebo 
twice daily. The primary endpoint was mortality dan 
morbidity.
The result  of this study showed that the rate of 
mortality was similar in the two treatment groups. 
The combined endpoint of mortality and morbidity 
(hospitalization, cardiac arrest with resuscitation and 
intravenous therapy) was significantgly reduced among 
patients in the valsartan group as compared to those in 
the placebo group. There were 723 patients of cases in 
the valsartan group and 801 cases in the placebo group 
(relative risk: 0.87, 95% confidence interval 0.77-0.97, 
p= 0.009). The value of CER was 32%, EER was 29%, 
RRR was 9,4%, ARR was 3% and NNT was 33.
 
Discussion
Sawada et al8studied the effect of ARB add on therapy 
on mortality and morbidity as compared to non ARB 
treatment. Beside cardiovascular complication, the 
endpoint also include cerebrovascular event, mortality 
and new onset diabetes.This study showed that 
the administration of valsartan therapy reduce the 
occurence of cardiovascular event as compared to non 
ARB therapy. The incidence of cardiovascular events 
was 5.5%  and 10.2% invalsartan add-on and non-
ARB groups, respectively. The relative risk reduction 
was 46% in the valsartan group as comparedto the 
non-ARB group. There was also lower rate of angina 
pectoris in valsartan group as compared to non-ARB 
group (RRR=48%).The administration valsartan was 
considered safe due to minimal adverse effects found 
througout the study. The NNT for cardiovascular 
prevention was 21, made valsartan a reasonable drug 
to be applied widely.
The study by Kasanuki H showed different result.9 
According to this study there was no significant 
difference in cardiovascular events between candesartan 
group and placebo group. This conflicting result might 
resulted from some limitations of the study which 
include the high usage (71%) of ACE-Inhibitors in 
the non-ARB therapy group and the low dose of 
candesartan used in the ARB group. However, the 
occurence of diabetes was lower in the candesartan 
group. This protective effect of candesartan on diabetes 
support the result of VALUE study12. According to this 
study ARBs were more effective in preventing diabetes 
compared to CCB.
The cardioprotective effect of valsartan is further 
ascertained in another study on valsartan performed by 
Cohn JN10.The third article by Cohn JN et al might 
have different patients characteristics as compared to 
our clinical question and the first two studies. This 
article studied the efficacy ofvalsartan as compared 
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to placebo for mortality and morbidity prevention 
among heart failure patients. Nevertheless, this study 
provide important information as addition to the first 
two studies, so we decided to include this study to the 
review.The result of this large scale study showed that 
valsartan was superior in reducing combined endpoint 
of mortality and morbidity (hospitalization, cardiac 
arrest with resuscitation and intravenous therapy) in 
patients with heart failure.Despite the high dose of 
valsartan (160 mg) used in this study, the drug was 
well tolerated and side effects were only slightly more 
prevalent in valsartan group. We do think the efficacy 
of valsartan still can be applied to hipertensive patients 
with heart failure. That is, under the assumption that 
the beneficial effects of valsartan among heart failure 
patients also apply to hypertensive patients with heart 
failure.
ARBs are well tolerated due to minimal side effects 
but the next intriguing question would be whether 
ARBs are as effective as ACE-Inhibitor in preventing 
cardiac events among high risk individual. According 
to two large scale studies (VALIANT study and 
ONTARGET study), ARBs are as effective as ACE-
inhibitors for cardiovascular endpoints among high 
risk patients. This primary endpoint include cardiac 
related mortality, myocard infarct and stroke.13,14
The administration of ARBs, in this case valsartan 
and candesartan, is considered safe due to the minimal 
side effect occured during the study. Beside efficacy 
and safety, one aspect to consider when prescribing 
drug in Indonesia is the price of the drug.Currently, 
with “out of pocket” payment system (instead of health 
care insurance) and the low economic background of 
some patients, made it prudent for clinician to always 
consider drug cost in every clinical decision. ARBs 
are usually more expensive than other hypertensive 
drugs, fortunatellysome ofthese drugs are now available 
as generic drugs. It would be wise for clinician to 
individually tailored every drug prescription according 
to patients clinical condition and socio-economic 
background.
One particular limitation of this report might 
related to the search strategy. In terms of the search 
strategy, we admit that we might have missed relevant 
articles due to the exclusion of all articles that were 
not available with full text on the internet. We only 
found two articles which perfectly related to our 
clinical question. Nonetheless both articles are large 
scale studies with adequate follow-up period and 
they reported similar benefit of ARBs (valsartan and 
candesartan). Clinical experience with these ARBs are 
quite extensive, for this reason ARBs can be considered 
as a cardioproective hypertensive agent for high risk 
hypertensive patients. 
Conclusion and recommendation
ARB therapy, represented by valsartan and candesartan 
in these studies, is effective in reducing cardiovascular 
event in high risk hypertensive patients (defined 
by patients withtype 2 diabetes mellitus, lipid 
metabolism abnormality, obesity, and heart failure). 
Valsartan therapy is well tolerated, as shown by the 
minimum adverse effects found throughout these 
studies. ARBs tend to be more expensive, therefore, 
the best implementation of this evidence requires 
risk factorsand socio-economic assestment of each 
patient.
This new insight can be translated into clinical 
practise. Based on this evidence, we recommend the 
administration of valsartan, an ARB drug, forhigh risk 
hypertensive patient in the clinical scenario mentioned 
above.
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